Table 1.
Baseline characteristics of patients.
Table 2.
a. Characteristics of carcinoembryonic antigen (CEA), cancer antigen (CA) 125, CA19-9, and CA15-3 in 184 patients with advanced lung adenocarcinoma. b. Items of 163 patients with advanced lung adenocarcinoma with evaluable tumor markers.
Fig 1.
Relevance between image-based response and the type of 4 tumor marker levels in 157 patients with advanced lung adenocarcinoma.
RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD-30 stable disease with tumor reduction <30%, SD+20 stable disease with tumor increasing <20%, PD progressive disease.
Fig 2.
Relevance between image-based response and type of CEA percentage of change over the 0th-14th day in 117 patients with advanced lung adenocarcinoma.
CEA carcinoembryonic antigen, RECIST Response Evaluation Criteria in Solid Tumors, PR partial response, SD-30 stable disease with tumor reduction <30%, SD+20 stable disease with tumor increasing <20%, PD progressive disease.
Fig 3.
Kaplan-Meier curves for progression-free survival (A) in the entire cohort, (B) in activated mutation, (C) in EGFR and ALK-negative/unknown groups, respectively. EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, d-PFS progression-free days.
Table 3.
Univariate and multivariate prediction of progression-free survival.